The NHLBI Family Heart Study is a multicenter, population-based study of genetic and nongenetic determinants of coronary heart disease (CHD), atherosclerosis, and cardiovascular risk factors. In phase I, 2,000 randomly selected participants and 2,000 with family histories of CHD were identified among 14,592 middle-aged participants in epidemiologic studies. Medical histories from these individuals, their parents, and their siblings were used to calculate family risk scores that compared the number of reported and validated CHD events with the number expected based on the size, sex, and age of family members. A total of 657 families with the highest risk scores and early-onset CHD and 588 randomly sampled families had clinic examinations that included electrocardiograms, carotid artery ultrasound scans, spirometry, measurements of body size, blood pressure, lipids, lipoproteins, hemostatic factors, insulin, glucose, and routine chemistries. Additional biochemical and genetic studies are being performed on selected participants. Serum, plasma, lymphocytes, red cells, and DNA are stored for future studies, including genotyping of candidate genes and anonymous markers. Contributions of genes, shared and individual environments, and behaviors to variations in risk factors, preclinical atherosclerosis, and CHD will be estimated. Linkage studies, including the quantitative trait loci approach, are planned. Aw J Epidemiol 1996;143:1219-28. coronary heart disease; genetics; hypertension; risk factors Coronary heart disease (CHD) is the leading cause of death and a major cause of illness and disability in US men and women. Forty-three percent of all deaths are attributed to cardiovascular disease (CVD), and more than half of these deaths are due to CHD. Risk factors for CHD are highly prevalent; in 1990, approximately 20 percent of the adult population had high levels of cholesterol, 26 percent had hypertension, 25 percent smoked cigarettes, and 33 percent were overweight, according to estimates from the Third National Health and Nutrition Examination Survey (1). Heredity is known to be a determinant of elevated blood cholesterol, blood pressure, obesity, and diabetes mellitus, and smoking habits run in families (2, 3). Nevertheless, a positive family history remains associated with incidence of CHD, even when the effects of these Received for publication April 24, 1995, and In final form April 1, 1996.
risk factors are controlled (3) (4) (5) . Thus, despite extensive knowledge of risk factors, improvements in treatment, and the substantial decline in CHD mortality during the past 25 years, much remains to be learned about genetic susceptibility and its interaction with lifestyle, behavior, and environmental exposures.
The National Heart, Lung, and Blood Institute (NHLBI) Family Heart Study was designed to identify and evaluate genetic and nongenetic determinants of CHD, preclinical atherosclerosis, and cardiovascular risk factors in individuals and families recruited from existing population-based studies (parent studies). The study is being conducted in two phases: phase I, the family history component; and phase II, the clinical examination and follow-up component. This paper provides an overview of the objectives and design of the study. Details of the methods are provided in the Manuals of Procedure (6) , available from the Coordinating Center.
In phase I, using family and personal histories and parent study information on probands, our objectives were 1) to characterize families with respect to histories of CHD and related conditions; 2) to determine the extent to which familial aggregation of known risk factors accounts for familial clustering of CHD; and 3) to identify families with high rates of CHD for clinic examinations in phase n.
In phase II, using information from the Family Heart Study examinations of families, our objectives were 1) to describe the degree and pattern of familial aggregation of CHD, noninvasively measured atherosclerosis, and CVD risk factors; 2) to estimate the contributions of genes, shared and individual environments, and behaviors to variation in risk factors as well as to preclinical and manifest disease; 3) to identify new genetic and nongenetic risk factors and protective factors for unexplained high or low rates of familial CHD; and 4) to evaluate interactions between genetic factors and personal behaviors or environmental exposures as determinants of CHD in individuals, families, and defined populations.
MATERIALS AND METHODS
Standardized questionnaires were used to ascertain family histories of coronary heart disease, other types of heart disease, stroke, high blood pressure, diabetes, cancer, and asthma (6) (figure 1). Reported CHD events were validated by having adult relatives provide medical histories for themselves and by reviewing medical records and death certificates. Families with high family risk scores (see below) and a random sample of families were offered clinical examinations and laboratory tests, including molecular genetic studies. Probands and their parents, siblings, spouses, and adult offspring were included.
Parent studies
Probands for the Family Heart Study are participants aged 45-69 years in three population-based epidemiologic studies, namely, the Framingham Heart Study, the Atherosclerosis Risk in Communities (ARIC) Study, and the Utah Health Family Tree Study in Salt Lake City, Utah. The ARIC Study is the source of two populations, one in Minneapolis, Minnesota, and the other in Forsyth County, North Carolina.
The Framingham Heart Study is a longitudinal investigation of constitutional, environmental, and genetic factors influencing the development of CVD in men and women. The Family Heart Study probands were chosen from the 2,650 independent families represented in the offspring and spouse population, which was recruited in the 1970s (table 1) . Extensive information about cardiovascular disease and its risk factors is available from repeated examinations. The parent generation, recruited in 1948, is the source of detailed information for parents of the probands selected for inclusion in the Family Heart Study (7).
ARIC is a multicenter, prospective study of the etiology of atherosclerosis and its clinical sequelae and The Utah Health Family Tree Study in Salt Lake City has collected, through questionnaires, histories of heart disease and other conditions for families of high school students. The parents of the students provided information about their parents, siblings, and offspring (9) . Clinical, biochemical, and genetic examinations and follow-up have been limited to members of approximately 500 CHD case and control families ascertained from the 50,000 families with computerized family history data. The Utah Study began in 1983, but only family histories ascertained in the 3 years preceding the Family Heart Study were used to select probands (table 1) ; the approximately 4,000 Family Heart Study probands were parents, uncles, or aunts of the students and were selected to achieve an age distribution similar to that of the other field centers.
Family Heart Study population
The numbers of probands at each site are shown in table 1. There were 14,592 potential probands; 13,910 white and 512 black men and women, 68 Asians, 23 American Indians, and 79 Hispanics. In Framingham and Salt Lake City, one potential proband was selected at random from each eligible sibship so that there are approximately 2,600-4,000 biologically unrelated probands at each site. In Framingham and at the two ARIC sites where extensive information, blood samples, and DNA were available from previous examinations, participants who subsequently died were acceptable as probands for the Family Heart Study.
Family risk scores
Family risk scores relate observed numbers of CHD events within a family to the numbers expected. For each individual, the estimated probability of an event was determined on the basis of the sex and age of the individual and the CHD incidence rates experienced in the Framingham Heart Study (10). For those who had had a CHD event, the age at which the first coronary event occurred was used. For those without an event, current age or age at death was used. The expected number of events (E) for a family was defined as the sum of the probabilities for the individual family members. The reported (observed) number of CHD events (O) was compared with the expected number using a simple formula of the type: Family Risk Score
(FRS) = (O-E)IJE.
High values of the risk score identify families with an excessive number of affected members beyond that which would be expected from their size, sex, and age distribution. These families tend to be those with early familial CHD. To compensate for high values of the risk score in young families with only one event, the family risk score was set to zero if (O -E) was less than or equal to 0.5. Thus, the final equation for assessing family risk was:
Scores that were greater than or equal to 1, but with only one observed event were set back to 0.99 to ensure that risk scores greater than 1 represented familial CHD. Details of the method have been published (11) . Prior to phase I, preliminary risk scores were calculated by using information available in the parent studies on probands, their parents, and some of their siblings. Risk scores were calculated again as more complete, up-to-date, and validated information became available. The final Family Risk Score was Am J Epidemiol Vol. 143, No. 12, 1996 based on age at onset of CHD in the proband, his or her parents, and siblings (figure 2). Information on children and spouses was not used to calculate family risk scores for the purpose of selecting high-risk families for phase II, but it will be used in analyses of familial and genetic data.
RESULTS

Phase I (June 1993 to July 1995)
Probands at each site were divided into three groups. Group 1 was a random sample of 500 probands; group 2 consisted of approximately 500 probands who were not in group 1 but had preliminary high family risk scores. Because the number of black participants in the study population was small, all 485 black probands in North Carolina were included in group 1. The remaining probands were designated as group 3. The probands in the random sample were identified first regardless of family risk score. Thus, the random samples include a complete range of family risk scores. The approximately 500 high-risk families at each site were selected from the remaining probands who were sorted in order of descending family risk score. Group 3 was included in analyses that used parent study data, but no additional information was collected in the Family Heart Study. Probands in groups 1 and 2 were asked to complete a family history questionnaire (figure 1) that provided new and updated information about both parents and all brothers, sisters, spouses, and offspring and indicated the blood relationship, vital status, date of birth, and state of residence for each of these individuals, whether living or deceased. Year of death and the state in which the death occurred were requested for deceased relatives. Probands were asked to record whether each relative had had a heart attack, balloon angioplasty, or coronary bypass surgery and, if they had, to record the age at which the first diagnosis or event occurred. Probands were also asked to record whether each relative had any other type of heart disease, stroke, high blood pressure, diabetes or high blood sugar, cancer, or asthma. To reduce the burden of reporting, information already available in parent studies was preprinted so that probands were asked only to provide new information.
The probands were also asked to complete a medical history questionnaire for themselves and to record the names and addresses of family members over age 25 years, provided they (the probands) were willing for the study to contact their relatives. The medical history questionnaire was then sent to these family members. Each family member was asked about his or her height, weight, and cigarette smoking and about any history of heart attack, angina, coronary bypass surgery or angioplasty, other heart disease, or stroke. Information was sought about hospitalizations for any of these conditions, and permission for release of records was requested. Questions were also asked about diagnoses of diabetes, high blood pressure, high blood cholesterol, asthma, and cancer. Information about age at diagnosis and treatment was requested for each condition.
The Family Heart Study medical histories are more recent than those in parent study records and provide self-reported rather than proxy information for relatives. If consent for their release was given, hospital records and death certificates were requested and reviewed to verify reported CHD events according to study criteria. Records of coronary bypass surgery, angioplasty, thrombolytic treatment, or old myocardial infarction were accepted as well as hospital discharge diagnoses or death certificate entries of CHD or acute myocardial infarction. The final step in assessing familial risk in phase I involved recalculation of risk scores by using validated events and earliest age at onset of CHD.
In summary, existing information on 14,592 participants in ongoing epidemiologic studies was used to identify 2,000 randomly selected individuals (approximately 500 at each site) and approximately 2,000 individuals with high family risk scores (approximately 500 at each site). These individuals and all 485 black participants in North Carolina were asked to participate in phase I of the Family Heart Study by providing family histories, names and addresses of their relatives, and medical histories for themselves. Approximately 25,000 relatives were subsequently asked to provide their own medical histories of CHD and related conditions. The numbers of probands and relatives who responded are shown in table 1 with response rates at each site. Data are available in phase I for 68 percent of probands and 86 percent of their relatives. Response rates were lowest for the black population (40 percent for probands and 59 percent for relatives) and highest for the white population in Framingham (83 percent for probands) and Minneapolis (94 percent for relatives). Because of the low response rate and the paucity of families with CHDaffected living members in the black population, phase I activities are continuing and being expanded to recruit high-risk black families from a clinic and local hospitals.
Phase II (February 1994 to December 1995)
In phase IT, adult members of 588 randomly selected families and 657 families with the highest risk scores were recruited for clinical examination and follow-up (table 2) . Selection of high-risk families was based on the number of CHD events, as well as the recomputed family risk score, using validated events. Families with two or more CHD events and risk scores of 0.5 or higher were considered to be eligible. Family members aged 25 years or older were offered clinic examinations provided that at least 50 percent of the eligible members, including at least two biologically related individuals, returned personal medical histories. Randomly sampled families were invited to clinic examinations using the same age and response criteria, but without regard to history of CHD. Eligibility criteria for black families were relaxed so that any two biologically related individuals constituted a family. Black families are classified according to family risk score and occurrence of CHD into two equal groups for analysis: higher and lower risk. The goal was to examine 80 percent of eligible family members. Family members not able to attend one of the clinics were offered abbreviated examinations at remote sites.
Components of the clinic examination are similar to those in the ARIC Study; they are shown in tables 3 and 4 and described in detail in the Manuals of Procedure (6) . Participants were asked to fast for 12 hours before coming to the clinic and to bring their medications with them. Names, concentrations, and frequency of use of prescribed and over-the-counter medications used in the 2 weeks prior to examination were recorded and coded (6) . The examination lasted about 3 and one-half hours and concluded with an exit in- terview. Individuals who needed further investigation or treatment were referred to their own physician. Electrocardiograms, ultrasound scans of carotid arteries, and pulmonary function tests were sent to reading centers for measurement and interpretation. Blood was sent to a central laboratory for analysis, extraction of DNA, and storage of frozen samples; lymphocytes were immortalized for members of CHD families. Results of laboratory tests, electrocardiogram, ultrasound, and pulmonary function procedures were included in the final reports sent to participants and to their physicians, if participants so wished.
In addition to the measurement and ascertainment of risk factors, diagnoses of CHD and other conditions were made in accordance with specified criteria (6 Annual follow-up of examined participants was designed to maintain contact and to update information on CHD events, hospitalizations for related conditions, and deaths from all causes.
Quality assurance and quality control
The protocol was detailed in a set of nine manuals of procedure that specify the equipment, conditions, preparation, and handling of the subjects and samples (6) . The Office of Management and Budget approved the study design, procedures, and forms. A pilot study tested all aspects of the data collection and data flow procedures through the Field Centers, the Reading Centers, and the Core Laboratory to the Coordinating Center. An independent NHLBI-appointed Monitoring Board reviewed and approved the plans and readiness of the agencies to conduct the study before data collection began and regularly reviews progress.
Quality assurance and quality control of the data were accomplished through training and certification of technicians, calibration and servicing of equipment, and logs of performance. The Coordinating Center prepared reports on the study progress and highlighted potential problems for the Steering Committee that made decisions regarding study conduct and protocol changes. Subcommittees on examinations, quality control, event validation, and publications monitor progress and make recommendations to the Steering Committee. Study coordinators and data managers at each site resolve day-to-day operational problems and assure that centers continue to operate consistently.
Monitoring visits were made to each Field Center, the Coordinating Center, the Central Laboratory, and the Reading Centers. Any deviations from the protocol were noted, and recommendations were made for the correction of any problems.
The interactive data entry and management system at the Field Centers detects errors and inconsistencies at entry, before they become a part of the database. Additionally, the Coordinating Center conducts extensive checks centrally and generates lists of suspicious data values to be validated against original field center records. Each Reading Center performs internal quality control measures and blind duplicate readings, and rates data for quality; feedback reports are generated for each technician. The Central Laboratory utilizes an additional blinded external quality control procedure, in which split samples are sent to the laboratory under "phantom" identification numbers. Kappa and intraclass correlations are used to assess the reliability of each measure.
Data management system and data flow
Phase I was supported by a distributed data entry/ management system running on three identical IBMcompatible PCs in an OS/2 environment at each field center. The system is a set of menu-driven SAS applications, utilizing the SAS/FSP (Full Screen Product), AF (Applications Facility), and SAS/GRAPH specifically designed at the Coordinating Center for the Family Heart Study (12). The integrated application allows generation of preprinted forms and mailing labels and bar code reading, supports date/time logging of all tasks (mailing, receipt, postcard reminders, tracing telephone calls, etc.); allows for the generation of prioritized lists of tasks yet to be accomplished; and provides local reports of study progress, data entry/ editing, and backup. All data sets as well as the entire application software are password protected, with varying levels of access supported (logging only, readonly, data entry/editing, data manager level access, etc.). Subject identification numbers are produced in bar-coded form whenever possible to reduce the probability of identification mismatches and to facilitate data entry. Once a week, each field center's database is assembled onto a single machine through removable media transfer (such as floppy or cartridge disk), archived, and mailed to the Coordinating Center. There the data are collated into a cumulative SAS/UNDC database (12) on a set of SUN workstations (SUN Microsystems, Mountain View, California), where further reports and analyses are performed.
The same computer equipment and similar data entry/management system also supports phase II activities. The preferred method of data collection and transfer for interviews is paperless, direct data entry by a trained interviewer. This allows immediate interactive checking for improper/impossible responses and eliminates transcription error. Paper forms are available as a backup for interviews and are used for measurements in which use of equipment is incompatible with direct computer entry. Data are collated onto a single machine at each field center and sent to the Coordinating Center on a weekly basis.
Electrocardiographic, pulmonary function, and ultrasound data are sent to the reading centers for processing. Summary data are then sent to the CoordinatAm J Epidemiol Vol. 143, No. 12, 1996 ing Center in batches via File Transfer Protocol on the Internet or on floppy disk. The Central Blood Laboratory sends the results electronically to the Coordinating Center. The Reading Centers and the Central Laboratory notify the Field Centers of "alert values."
Data analysis
Distributions of genetic, behavioral, physical, biochemical, and environmental risk factors; preclinical atherosclerosis; and coronary heart disease will be compared in affected and unaffected members of families with high rates of CHD, and these individuals and families will be compared with individuals and families who represent the populations from which the high-risk families came.
Phase I data will be used to determine the extent and pattern of familial aggregation of self-reported CHD, stroke, hypertension, diabetes, cancer, and asthma and of established risk factors, including high levels of cholesterol and blood pressure, cigarette smoking, obesity, and diabetes. Relations among causes of death, age at death, and self-reported diseases and risk factors will be investigated in families. Clinical and laboratory data available from parent studies for probands will also be analyzed according to family risk score.
Risk scores quantify the familial nature of CHD better than the more traditional positive or negative family history does. In a multivariate risk model predicting CHD in probands from the traditional risk factors plus positive or negative family history, the residual Family Risk Score (computed excluding the subject himself) is a significant independent predictor. The degree of correlation between the Family Risk Score and the traditional risk factors assesses the extent to which familiality of CHD is accounted for by inheritance of known risk factors or suggests that previously undetected high-risk genotypes may exist.
Extensive familial and genetic modeling of each of the clinical risk factors and of CHD itself will be performed by using data collected in phase II. Techniques such as the recently developed program SEG-PATH (13) will be used to do combined segregation and path analysis (variance components) to infer the degree and character of unmeasured genetic contribution to total variance. Multivariate modeling will be used to assess association and/or linkage to candidate genes and markers. For many risk factors, the degree of contribution from the genotype is uncertain (e.g., lipoprotein(a), fibrinogen, atherosclerosis in carotid arteries) or controversial (e.g., blood pressure, body mass index, fat patterning, obesity, and the insulin resistance syndrome). Specific candidate genes for phenotypes of interest will be included selectively in multiple regression models (measured gene approach). For association models, the generalized estimating equations approaches of Liang and Zeger (14) can also be used to include all of the family data efficiently to estimate the effects of these genes, properly correcting for the lack of independence between family members. Families that appear to be segregating for a major gene for a trait will be targeted for linkage analysis by using selected DNA markers. The sample of high-risk families will provide most of this information, whereas the random sample of families will be used to estimate many of the nuisance parameters in parametric linkage analysis (such as founder gene frequency and mode of transmission) that are critical to obtaining correct results.
Contrasting a random sample of families with a high familial risk sample provides an opportunity to address the genetic etiology of CHD. The high-risk sample can be corrected for ascertainment bias by incorporating the family risk score itself into the models. Determining whether the random and high-risk samples are homogeneous or heterogeneous with respect to the parameters of the major gene models for a given phenotype (after correction for ascertainment) will test whether the genetic etiology of the CHD phenotype is different in different families. Families can then be divided into homogeneous subsets with respect to their evidence for a segregating major gene (15) and followed up for further DNA processing and linkage studies, possibly with extension of the pedigrees.
DISCUSSION
The NHLBI Family Heart Study is a unique, multicenter genetic epidemiology study of early-onset CHD in families and of inherited and behavioral causes of CHD, atherosclerosis, and cardiovascular risk factors in defined populations. Advances in molecular genetics and increasing knowledge of genes involved in the regulation and function of the cardiovascular system, as well as extensive knowledge of the role of lifestyles, behavioral factors, and physiologic characteristics, make this an opportune time to conduct population-based studies of familial, genetic, and nongenetic determinants of CHD. Statistical techniques are available for estimating the contributions of genes, environment, and their interaction to variability in risk factors, preclinical disease, and manifest complex diseases of multifactorial etiology, such as CHD.
A family history of CHD at a young age is a strong, independent risk factor for CHD. The relative hazard of death from CHD was increased eight to 15 times in monozygotic twins when one twin died of CHD before age 55 years, but the genetic effect decreased at older ages (16) . Family studies also found excess CHD mortality in siblings and offspring of individuals with early-onset CHD (3) (4) (5) . Estimates of heritability indicate that up to 50 percent of within-population variance in levels of blood cholesterol, blood pressure, and body mass index is attributable to inheritance (2) . Members of families also share behaviors and exposures, including dietary and smoking habits, patterns of physical activity, socioeconomic circumstances, and psychosocial characteristics that have been linked to cardiovascular disease (3, 9) . Nevertheless, a positive family history of CHD remains associated with CHD even when the effects of these risk factors are controlled (3) (4) (5) . To a degree yet to be determined, interactions between genetic factors and environmental influences determine susceptibility to and development of disease.
The extent of familial aggregation and genetic contributions to newer or suspected risk factors, such as high density lipoprotein cholesterol, lipoprotein(a), low density lipoprotein cholesterol particle size and density, fibrinogen, plasminogen activator-inhibitor-1 and other hemostatic factors, insulin, homocysteine, and atherosclerosis in peripheral arteries has not been determined adequately in population-based samples of individuals and families in the US population. Constellations of risk factors have been detected recently; they include high blood pressure, dyslipidemia, glucose intolerance, hyperinsulinemia, and obesity in clusters variously characterized as familial dyslipidemic hypertension, the insulin resistance syndrome, or syndrome X (17, 18) . Associations between a deletion polymorphism in the angiotensin-converting enzyme gene and myocardial infarction and between mutations of the angiotensinogen gene and hypertension have been found in some studies, but not in others (19) (20) (21) (22) (23) . Interaction between angiotensin-converting enzyme gene and angiotensinogen and angiotensin II receptor gene polymorphisms have also been associated with CHD, but these interactions have been detected in small samples and account for a small fraction of CHD events (24) .
Presentation of CHD at an early age is relatively rare, and recruitment of multiply affected families in sufficient numbers to assure adequate power for genetic epidemiology studies requires large populations. Costs of ascertaining and validating family histories of CHD in defined populations would be prohibitive if they were undertaken de novo. The NHLBI Family Heart Study has tapped preliminary information on familial CHD available from existing studies. The recruitment of 657 high-risk CHD families amounts to about a 5 percent yield from close to 14,500 potential probands. The approximately equal number of randomly selected families provides a comparison group representing the populations from which the CHD cases came. Seven percent of these families met our criteria for high CHD risk. Random families include the full range of family risk scores and affected and unaffected CHD families and individuals; they provide measures of the prevalence and distribution of risk factors and protective factors. They are a source of families with low rates of CHD, including those with or without known risk factors. Population frequencies of genes related to CHD or risk factors can be determined and estimates made of absolute, relative, and attributable risks for genetic and nongenetic factors and their interactions.
